Evercore ISI Reiterates Bullish View on Adamas Pharmaceuticals (ADMS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Adamas Pharmaceuticals (ADMS) PT Lowered to $7 at Piper Jaffray
December 17, 2019 1:57 PM ESTPiper Jaffray analyst David Amsellem lowered the price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $7.00 (from $11.00) while maintaining a Overweight rating.
MS gait not dead, but certainly not alive and well... MoreAdamas Pharma (ADMS) Resumes After Halt for News, Now Halted on LUDP
December 17, 2019 9:51 AM ESTAdamas Pharma (NASDAQ: ADMS) Resumes After Halt for News, Now Halted on LUDP
... MoreAdamas Pharma (ADMS) to Resume Trading at 9:50 am ET
December 17, 2019 9:04 AM ESTAdamas Pharma (NASDAQ: ADMS) to Resume Trading at 9:50 am ET
... MoreAdamas (ADMS) phase 3 trial of ADS-5102 for MS patients with walking impairment met its primary endpoint, did not demonstrate significant effect on secondary walking measures
December 17, 2019 9:03 AM ESTAdamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that INROADS, a 3-arm, randomized, double-blind, placebo-controlled study in 594 multiple sclerosis (MS) patients with walking impairment met its primary endpoint.
Results from the study showed that patients taking 274 mg ADS-5102 had a statistically significant improvement in response rate of 21.1% compared to 11.3% taking placebo (p=0.01). Response was defined as at least a 20% improvement in walking speed from baseline to 12 weeks post-treatment, as measured... More
